Lutetium Lu 177 NYM032

{
  "id": "MLC-T-ONC-014920",
  "term": "Lutetium Lu 177 NYM032",
  "field": "Oncology and biomedicine",
  "definition": "A radioconjugate composed of NYM032, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration, lutetium Lu 177 NYM032 targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by direct cytotoxicity through beta radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors.",
  "synonyms": [
    "177Lu-labeled NYM032",
    "177Lu-NY108",
    "177Lu-NYM032",
    "lutetium Lu 177 NY 108"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lutetium-lu-177-nym032/"
}